Form 4: Director Stefan Dyckerhoff Sells Astera Labs Shares

Director Stefan Dyckerhoff sold a total of 12,499 shares of Astera Labs, Inc. common stock on May 7, 2026, pursuant to a Rule 10b5-1 trading plan.

Summary

• Director Stefan Dyckerhoff executed a series of sales of Astera Labs (ALAB) common stock on May 7, 2026.
• A total of 12,499 shares were sold across direct holdings, a trust, and a limited partnership.
• The sales were conducted at weighted average prices of $199.00 and $201.102 per share.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on December 1, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were executed under a pre-planned 10b5-1 arrangement, which is standard practice for corporate insiders.

Positives

• The sales were pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct and indirect beneficial ownership of the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person disclaims beneficial ownership in shares held by trusts and limited partnerships except as to their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the semiconductor and technology sectors, often used by executives to diversify personal portfolios while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings to avoid potential insider trading allegations.
• The scale of the sale is relatively minor compared to the total outstanding shares of a company in the high-growth semiconductor space.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the pre-planned nature of the sale mitigates concerns regarding negative sentiment.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Astera Labs, ALAB, Insider Trading, Form 4, Stefan Dyckerhoff, Rule 10b5-1